The Claim
Polyendocrine metabolic ovarian syndrome is an independent risk factor for pregnancy complications that is not adequately recognized in current antenatal guidelines and clinical practice.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Polyendocrine metabolic ovarian syndrome increases the risk of complications during pregnancy, but current prenatal care guidelines and medical practice do not consistently identify it as a distinct risk factor.
See the scientific wording
Polyendocrine metabolic ovarian syndrome (PMOS) is poorly recognized as an independent risk factor for pregnancy complications in current antenatal guidelines and clinical practice, despite evidence linking it to multiple adverse outcomes.
Women with this condition have high insulin and testosterone levels even before pregnancy. When they become pregnant, the body's natural increase in insulin resistance and hormone changes worsen these imbalances. The placenta cannot form properly, blood vessels in the uterus don't expand enough, and inflammation rises. This causes high blood pressure, high blood sugar, early labor, and babies that are too small or born too early.
What the research says
1 studyStudy: Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes.
Even though doctors know that women with PMOS have more pregnancy problems, most prenatal care rules still don’t treat PMOS as a special risk — this study says that’s a problem and new guidelines are finally starting to fix it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.